AR041086A1 - Vacuna - Google Patents

Vacuna

Info

Publication number
AR041086A1
AR041086A1 ARP030103127A ARP030103127A AR041086A1 AR 041086 A1 AR041086 A1 AR 041086A1 AR P030103127 A ARP030103127 A AR P030103127A AR P030103127 A ARP030103127 A AR P030103127A AR 041086 A1 AR041086 A1 AR 041086A1
Authority
AR
Argentina
Prior art keywords
immunogens
refers
neutralization
present
atopic
Prior art date
Application number
ARP030103127A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220212A external-priority patent/GB0220212D0/en
Priority claimed from GB0304672A external-priority patent/GB0304672D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR041086A1 publication Critical patent/AR041086A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

La presente se refiere a inmunógenos aislados y su uso en el tratamiento de enfermedades que se pueden tratar con neutralización de IL-13, tal como COPD, asma y trastornos atópicos tal como fiebre de heno, alergias de contacto y dermatitis atópica. En particular se refiere a la neutralización de los efectos biológicos de IL-13 mediante la inducción de una respuesta inmune contra la IL-13 mediante la vacunación de un mamífero con inmunógenos que comprenden la frecuencia de aminoácidos mutada o nativa de IL-13, y epítopos auxiliares de células T extranos bien insertados o unidos a la secuencia de IL-13 o presentes en polipéptidos vehículos- La presente también proporciona vacunas de DNA que comprenden una secuencia de polinucleótidos que codifica los inmunógenos de la presente. Se refiere adicionalmente a composiciones farmacéuticas que comprenden dichos inmunógenos y su uso en medicina y a procedimientos para su producción.
ARP030103127A 2002-08-30 2003-08-28 Vacuna AR041086A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0220212A GB0220212D0 (en) 2002-08-30 2002-08-30 Vaccine
GB0304672A GB0304672D0 (en) 2003-02-28 2003-02-28 Vaccines

Publications (1)

Publication Number Publication Date
AR041086A1 true AR041086A1 (es) 2005-04-27

Family

ID=31980003

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103127A AR041086A1 (es) 2002-08-30 2003-08-28 Vacuna

Country Status (8)

Country Link
US (1) US20060147417A1 (es)
EP (1) EP1532172A2 (es)
JP (1) JP2006503017A (es)
AR (1) AR041086A1 (es)
AU (1) AU2003259358A1 (es)
CA (1) CA2496409A1 (es)
TW (1) TW200407162A (es)
WO (1) WO2004019974A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1534323A2 (en) * 2002-08-30 2005-06-01 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
LT2805728T (lt) 2003-12-23 2020-05-25 Genentech, Inc. Nauji anti-il 13 antikūnai ir jų naudojimai
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
DE602005025525D1 (de) 2004-11-17 2011-02-03 Amgen Inc Vollständige humane monoklonale antikörper gegen il-13
GB0615881D0 (en) * 2006-08-10 2006-09-20 Univ Southampton Novel peptide for treatment of asthma
KR100956893B1 (ko) * 2006-09-25 2010-05-11 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
WO2011003138A1 (en) * 2009-07-06 2011-01-13 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor
US20160166637A1 (en) * 2013-08-02 2016-06-16 Virginia Tech Intellectual Properties, Inc. Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
AU2022330351A1 (en) * 2021-08-20 2024-04-04 Neovacs mRNA VACCINES COMPRISING IL-4 AND/OR IL-13 RNA AND USES THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
US6296843B1 (en) * 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
EA200101125A1 (ru) * 1999-04-23 2002-04-25 Фармекса А/С Способ понижающей регуляции активности il5
CA2404763A1 (en) * 1999-11-11 2001-05-17 Raj K. Puri Mutated il-13 molecules and their uses
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens

Also Published As

Publication number Publication date
CA2496409A1 (en) 2004-03-11
WO2004019974A3 (en) 2004-07-22
WO2004019974A2 (en) 2004-03-11
AU2003259358A8 (en) 2004-03-19
TW200407162A (en) 2004-05-16
EP1532172A2 (en) 2005-05-25
AU2003259358A1 (en) 2004-03-19
JP2006503017A (ja) 2006-01-26
US20060147417A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
AR041086A1 (es) Vacuna
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
ES2662801T3 (es) Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas
WO2011163628A3 (en) Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
AR047392A1 (es) Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TW200806316A (en) Yeast-based vaccine for inducing an immune response
MX338294B (es) Novedoso inmunotratamiento contra diversos tumores incluidos tumores neuronales y cerebrales.
MX336839B (es) Formacion de complejos de acidos nucleicos con componentes cationicos entrelazados por disulfuro para transfeccion e inmunoestimulacion.
MX2009002816A (es) Proteinas de fusion de albumina.
WO2011113819A3 (en) Diagnosis and treatment of cancer based on avl9
DE602005015990D1 (de) Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
AR061930A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
WO2009117116A3 (en) Heat shock protein gp96 vaccination and methods of using same
BR112015005987A2 (pt) vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
EP2700708A3 (en) Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
MD4481C1 (ro) Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV
DE602004028029D1 (en) Rwendung
ATE473756T1 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
WO2019098759A3 (ko) 형질전환된 인간세포 및 이의 용도
ATE520708T1 (de) Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal